Last updated on February 2019

A Study to Evaluate the Efficacy Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder


Brief description of study

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.

Clinical Study Identifier: NCT03375203

Contact Investigators or Research Sites near you

Start Over

Study Contact

Lincoln Research
Lincoln, NE United States
0.39miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.